Del Favero G, Fabris C, Panucci A, Basso D, Plebani M, Baccaglini U, Leandro G, Burlina A, Naccarato R
Bull Cancer. 1986;73(3):251-5.
In order to ascertain the clinical usefulness of CA 19-9 in detecting pancreatic cancer in comparison with CEA, and to verify the influence of age and liver dysfunction on serum levels of these two antigens, serum CA 19-9 and CEA were assessed in 32 control subjects, 32 patients with pancreatic cancer, 26 with chronic pancreatitis and 43 with gastrointestinal extra-pancreatic diseases. Sensitivity, specificity and diagnostic accuracy of CA 19-9 and CEA in detecting pancreatic cancer were: 69% and 44%, 91% and 75%, 60% and 19% respectively. Linear correlations were observed between the age of the subjects on the one hand and CA 19-9 or CEA on the other. Significant relationships were also noticed between alanine-amino-transferase or bilirubin serum levels and CA 19-9 values. Serum CA 19-9 seems to be a better diagnostic tool than CEA in the assessment of pancreatic cancer; nevertheless the influence of liver dysfunction and age to some extent limits the diagnostic value of CA 19-9.
为了确定与癌胚抗原(CEA)相比,糖类抗原19-9(CA 19-9)在检测胰腺癌中的临床实用性,并验证年龄和肝功能障碍对这两种抗原血清水平的影响,对32名对照受试者、32名胰腺癌患者、26名慢性胰腺炎患者和43名胃肠道胰腺外疾病患者的血清CA 19-9和CEA进行了评估。CA 19-9和CEA检测胰腺癌的敏感性、特异性和诊断准确性分别为:69%和44%、91%和75%、60%和19%。一方面观察到受试者年龄与另一方面CA 19-9或CEA之间存在线性相关性。还注意到丙氨酸转氨酶或胆红素血清水平与CA 19-9值之间存在显著关系。在评估胰腺癌时,血清CA 19-9似乎是比CEA更好的诊断工具;然而,肝功能障碍和年龄的影响在一定程度上限制了CA 19-9的诊断价值。